### Mid-term Business Plan 2018-2020 PROACTIVE

## Revised Major Objectives

### Sales

# Over JPY 100 bill.

Consolidated annual sales of 100 billion yen

105.1 billion yen (FY2018)

## Operating profit (accumulative)

More than JPY 40 bill.

- Maintenance and improvement of stable supply system
- Investment for sustainable growth (including new business investment)
- · Stable return to shareholders

### Capital-to-asset ratio

# More than 50%

Improvement of financial stability

## R&D cost (accumulative)

# More than JPY 26 bill.

- Development plan to ensure timely launch of new products
- Improvement of products satisfying demands of patients and MDs

### Investments

(accumulative)

# More than JPY 20 bill.

Investments to maintain and improve stable supply system

### **Dividend policy**

# Stable dividend

Contribution to share holders by keeping stable dividend and occasional reacquisition of own shares, etc. if necessary

### Mid-term Business Plan 2018-2020 PROACTIVE

## **Revised Assumptions**

Generic drug usage ratio 80% is achieved and maintained as mentioned in Basic Policy on Economic and Fiscal Management and Reform 2017.

No dramatic change in NHI drug price system from the time the Mid-term Business Plan was made.

NHI drug price revision in 2019 is only for reflection of consumption tax rate change, and regular NHI drug price revision is implemented in April 2020.

No change in consolidation in financial statement.

#### Disclaimer

This presentation contains forward-looking statements related to management's expectations about future business conditions. Actual business conditions may differ significantly from management's expectation and accordingly affect the Company's sales and profitability. Actual results may differ because of factors over which the Company has no control, including unexpected changes in competitive and economic conditions, government regulations, technology and other factors.

#### **Contact information**

Public Relations and Investor Relations Office Towa Pharmaceutical Co., Ltd.

ir@towayakuhin.co.jp TEL. +81-6-6900-9102 FAX.+81-6-6908-6060

